Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers

  • D. Luke Fischer
  • , Lea T. Grinberg
  • , Jared T. Ahrendsen
  • , Thomas G. Beach
  • , Kevin F. Bieniek
  • , Rudolph J. Castellani
  • , Rati Chkheidze
  • , Inma Cobos
  • , Mark Cohen
  • , John F. Crary
  • , Dennis W. Dickson
  • , Brittany N. Dugger
  • , Sara R. Dunlop
  • , Kurt Farrell
  • , Bernardino Ghetti
  • , Mohammad Haeri
  • , William Harrison
  • , Elizabeth Head
  • , Annie Hiniker
  • , Eric J. Huang
  • Anita Huttner, Pouya Jamshidi, Alifiya Kapasi, C. Dirk Keene, Julia Kofler, Caitlin S. Latimer, Ann C. McKee, Karin Mente, Michael B. Miller, Thomas J. Montine, Meaghan Morris, Melissa E. Murray, Peter T. Nelson, Kathy L. Newell, Richard J. Perrin, Biswarathan Ramani, R. Ross Reichard, Subhojit Roy, Johannes C.M. Schlachetzki, William W. Seeley, Geidy E. Serrano, Salvatore Spina, Andrew F. Teich, Shih Hsiu J. Wang, Thomas Wisniewski, Edward B. Lee

Research output: Contribution to journalComment/debate

Abstract

Our understanding of Alzheimer's disease (AD) and related dementias (ADRD) has grown exponentially, thanks to significant investments by the National Institute on Aging (NIA). This article celebrates the 40th anniversary of the NIA's Alzheimer's Disease Research Centers, highlighting the pivotal role of neuropathology as the bedrock for neurodegeneration research. Neuropathology has championed the key principles of proteinopathy, selective vulnerability, and stereotypic spread. Furthermore, neuropathologic studies advanced our understanding of ADRD prevalence, heterogeneity, clinical–pathological correlations, and genetic underpinnings, spurring biomarker development for target engagement and disease monitoring. Disease-modifying therapies for AD were inspired and informed by neuropathology. The neuropathology community is poised to refine diagnostics, leveraging digital pathology and integrating genetics and pathomics to enhance subtyping for novel precision medicine approaches. Despite some common misconceptions and logistical challenges, neuropathology continues to be a critical component of the ADRD research infrastructure, serving as a key bridge between allied basic and clinical sciences. Highlights: We celebrate 40 years of NIA-funded ADRCs and their contributions through neuropathology studies that have significantly advanced our understanding and treatment of ADRD. Neuropathology uncovers principles of neurodegenerative disease: proteinopathy, selective vulnerability, and stereotypic spread, informing diagnostics and therapies. Development of AD biomarkers with reference to neuropathology enhances accuracy in diagnosis and monitoring, paving the way for targeted disease-modifying therapies. Integration of digital pathology, genetics, and novel tools in neurodegeneration research promises advanced precision medicine approaches and refined diagnostics. Misconceptions and logistical challenges to neuropathological research are addressed to improve understanding and collaboration.

Original languageEnglish
Article numbere70734
JournalAlzheimer's and Dementia
Volume21
Issue number10
DOIs
StatePublished - Oct 2025

Keywords

  • Alzheimer disease
  • dementia
  • neurodegenerative diseases
  • neuropathology
  • pathomics

Fingerprint

Dive into the research topics of 'Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers'. Together they form a unique fingerprint.

Cite this